US44842L1035 - ADR
HUTCHMED CHINA-ADR
NASDAQ:HCM (1/15/2025, 12:08:12 PM)
13.845
-1.16 (-7.76%)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. The company employs 1,970 full-time employees The company went IPO on 2006-05-19. The firm operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
HUTCHMED CHINA-ADR
48th Floor, Cheung Kong Center, 2 Queen's Road Central
Hong Kong
P: 85221281188
CEO: Christian Hogg
Employees: 1970
Website: https://www.hutch-med.com/
— Indication expands to include treatment-naïve patients — — The 2021 conditional approval in previously treated patients converted to full approval — ...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today...
— HUTCHMED continues to deliver on its strategy outlined in November 2022 to create value, prioritize its portfolio and bring innovative medicines to...
Here you can normally see the latest stock twits on HCM, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: